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Robert Lawrence4, Brady McFarlane3, George Tadros5, Basil H. Ridha6, Carol Bannister7, Zuzana Walker8,
Hilary Archer9, Elizabeth Coulthard9, Ben R. Underwood10, Aparna Prasanna11, Paul Koranteng12, Salman Karim13,
Kehinde Junaid14, Bernadette McGuinness15, Ramin Nilforooshan16, Ajay Macharouthu17, Andrew Donaldson18,
Simon Thacker19, Gregor Russell20, Naghma Malik21, Vandana Mate22, Lucy Knight23, Sajeev Kshemendran24,
John Harrison25,26, Christian Hölscher27, David J. Brooks1,28, Anthony Peter Passmore15, Clive Ballard7 and
Paul Edison1,29*
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After publication of our article [1] the authors have
notified us that the name of Prof. Christian Hölscher had
been inadvertently forgotten when compiling the list of
authors. Dr. Hölscher developed the concept of testing
liraglutide in Alzheimer’s mouse model, has done the
preclinical experiments, and is a co-applicant of the
Alzheimer Society UK grant that partially funds the study.
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